Amicus Therapeutics Inc. Reports $10,000 in Q4 Lobbying Efforts
Recently disclosed lobbying activities by Amicus Therapeutics Inc. reflect a spend of $10,000 in Q4 2024. Key areas of focus included:
“newborn screening, prescription drug affordability”
For more detailed information on corporate lobbying, visit Quiver Quantitative.
Recent Insider Trades at FOLD
In the past six months, insiders at Amicus Therapeutics (FOLD) conducted six trades on their stock. Notably, there were no purchases, only sales.
Here’s a closer look at these insider transactions:
- BRADLEY L CAMPBELL (President and CEO) conducted all six trades, selling 45,401 shares without making any purchases.
For tracking insider transactions, check out Quiver Quantitative’s insider trading dashboard.
Hedge Fund Movements in FOLD Stock
Recently, 146 institutional investors increased their stakes in FOLD shares, while 113 reduced their holdings during the last quarter.
Some significant changes include:
- JANUS HENDERSON GROUP PLC decreased their holdings by 6,896,159 shares (-52.1%) in Q3 2024.
- AVORO CAPITAL ADVISORS LLC cut back on 4,225,000 shares (-15.4%) during the same period.
- Conversely, WELLINGTON MANAGEMENT GROUP LLP added 2,856,101 shares (+13.5%) in Q3 2024.
- PICTET ASSET MANAGEMENT HOLDING SA removed 2,588,334 shares (-61.4%) from their portfolio in Q3 2024.
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC increased their stake by 2,579,599 shares (+19.8%) in Q3 2024.
- REDMILE GROUP, LLC decreased their holdings by 2,348,497 shares (-22.2%) in Q3 2024.
- Lastly, DEUTSCHE BANK AG cut 2,254,799 shares (-75.4%) from their portfolio in Q3 2024.
To keep an eye on hedge fund activity, navigate to Quiver Quantitative’s institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative’s disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
